GlobalDatas pharmaceuticals report, Afatinib (Breast Cancer) - Analysis and Forecasts to 2020 provides Afatinib sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Reasons to buy
Afatinib, Breast cancer, Sales forecast, Phase III, Phase 3, Tyrosine Kinase Inhibitor (HER2, EGFR inhibitor), Competitors to Neratinib, Afinitor and Taxotere, Boehringer Ingelheim, Targeted therapy, Breast cancer, pipeline